Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. (STOK): 4 pipeline candidates · 1 upcoming catalyst · ~17 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
16.9 months
D/E 0.12 · 1% dilution
Lead: Phase 3
4 candidates
1 upcoming, next in ~836d
0 buys · 30 sells (180d)
A transparent, data-derived signal for Stoke Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.8B
Cash
$155.7M
Quarterly Burn
$60.6M
Runway
16.9 mo
Revenue
$6.2M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| stk-001 - multiple ascending doses | Phase 1/Phase 2 |
| stk-001 - single ascending doses | Phase 1/Phase 2 |
| stk-002 | Phase 1 |
| zorevunersen | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
196
Total value held
$2.20B
| Holder | Shares | Value |
|---|---|---|
| rtw investments, lp | 5,623,525 | $183.1M |
| blackrock, inc. | 5,385,714 | $175.4M |
| fmr llc | 5,383,666 | $175.3M |
| lynx1 capital management lp | 4,763,673 | $155.1M |
| vanguard capital management llc | 4,711,206 | $153.4M |
| morgan stanley | 3,423,280 | $111.5M |
| baker bros. advisors lp | 3,336,697 | $108.6M |
| toronto dominion bank | 3,173,258 | $103.3M |
| wellington management group llp | 3,095,700 | $100.8M |
| bvf inc/il | 2,547,557 | $82.9M |
Showing top 10 of 196 institutional holders of Stoke Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Stoke Therapeutics, Inc.'s pipeline?
Stoke Therapeutics, Inc. (STOK) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Stoke Therapeutics, Inc.'s lead drug candidate?
Stoke Therapeutics, Inc.'s most advanced tracked candidate is stk-001 - multiple ascending doses (Phase 1/Phase 2) for Dravet Syndrome.
What is Stoke Therapeutics, Inc.'s next catalyst?
Stoke Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Eva" — expected October 1, 2028.
What is Stoke Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Stoke Therapeutics, Inc. has approximately 16.9 months of cash runway.
What is Stoke Therapeutics, Inc.'s market capitalization?
Stoke Therapeutics, Inc.'s market capitalization is approximately $1.8B.
Get the full picture on Stoke Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.